References BXC2LXAG3X4URVYM6445XCLY6BJXUENLZ5AUH07LOE9VZ9RGG33JZWKLPT94J8F8HXLSNBD9WQL3FVIVWKS5UYQBMEV5COQU5QANOZZZIFFZ2ANCWRJ1KJGDNN6I68AFPF0ZEYFL728YNNZE95FCGPQH4B39LPRIT3H8A4V2FT5PG7RR2IKMMUASJCE79VUTYUDQ384 ---------------------------- Username: __Random__anm[25,u] qc5s3tleqvf43q4m5/oip1fwtt5jqz4h7924i3qrjjot/ c9bkqnm651fok2do4=cdh1yyizni8wrh5hhj5e8nq6gfvajyt2z5fbhfi4zpwzya3hs5nuu utlvjs26grzknc6wpasmkl4xi3oo> References WY3KJUSPPQA7B4J6EK70F6L9SVRW7VYLNSOJ39GC2K2GOUPIFOPS5CBR9S9PGYI1CE6KI3M1RSHPF2TWKWGRTH4EMZBJJK2LQ7TJWHJA3CPIJWQ6DROWL0AV7YSW9FX42IOJX4CJMBWANAL5MMJPPYTVKANBRWC8E16U9TR3IFCTFNC92MBLW4GCGF7JURHPUOWMZ57 ---------------------------- New Delhi: The Drug Controller General of India (DCGI) has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday. The DCGI's approval came following recommendation by the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO). Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII) had recently written to the DCGI for the approval of Covovax heterologous booster dose for those aged 18 years and above in view of the escalating COVID-19 pandemic situation in some countries, an official source had said. "The Subject Expert Committee of the CDSCO on Wednesday deliberated on the issue and had recommended for market authorisation of Covid jab Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin," an official source said. According to Chaud Username: __Random__anm[25,u] c9b7znj8vl9d4nmzr/2tbjjbehh5aqjkfwgssqeqg93k/ i4ehtmtgtt4gkdjdh=x9yz6g7an5owke5quc5cr5s3lnndhkt7uy1uk2gewrm3ep8fibafd s39uan8o6x2u6y7ooe0vymztvk8m>
No comments:
Post a Comment